Cargando…
Exploring a New Entity of Single-Agent Pembrolizumab-Associated Hypophysitis
Hypophysitis is the inflammation of the pituitary gland primary or secondary to local or systemic disease. It tends to occur more with cytotoxic T-lymphocyte-associated protein 4 inhibitors (10-15% of cases), which is a different entity compared to that associated with anti-program death 1 (anti-PD1...
Autores principales: | Balti, Eric, Verhaeghe, Sarah, Kruse, Vibeke, Roels, Stijn, Coremans, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481187/ https://www.ncbi.nlm.nih.gov/pubmed/36127991 http://dx.doi.org/10.7759/cureus.27763 |
Ejemplares similares
-
Pembrolizumab-Induced Hypophysitis With Isolated Adrenocorticotropic Hormone (ACTH) Deficiency: A Rare Immune-Mediated Adverse Event
por: Doodnauth, Andrew V, et al.
Publicado: (2021) -
Immunotherapy-Induced Anterior Hypophysitis
por: Pachika, Pranali S, et al.
Publicado: (2021) -
Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies
por: Chaudry, Abdul, et al.
Publicado: (2020) -
Neurosarcoidosis-Induced Hypophysitis Mimicking Pituitary Macroadenoma
por: Ach, Taïeb, et al.
Publicado: (2023) -
Early Detection of Immune-Mediated Hypophysitis With Use of Checkpoint Inhibitor Immunotherapy
por: Yossef, Kristena, et al.
Publicado: (2022)